{"schema_version":"1.0","type":"article","title":"DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？","url":"https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.md","lang":"zh-Hant","date":"2026-05-11","publish_at":"2026-05-11T10:30:00+08:00","updated_at":"2026-05-11","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","ADC","PROTAC"],"summary":"【強強聯手！當 ADC 遇上 PROTAC】生醫圈有兩個絕對頂流。📌 一個是 ADC（Antibody-Drug Conjugate，抗體藥物複合體）。📌 另一個是以 PROTAC（Proteolys","key_points":[],"facts":[],"sections":["01｜什麼是 DAC？ADC 的 GPS，加上蛋白降解劑的粉碎機","02｜為什麼需要 DAC？因為單純 PROTAC 太難全身給，單純 ADC 又太像化療","03｜Orum Therapeutics：DAC 領域最早跑進臨床的先鋒","04｜C4 Therapeutics + Roche：大型藥廠開始正式下注 DAC","05｜Firefly Bio、Prelude Therapeutics：新銳黑馬已經開始搶位","06｜DAC 的三個核心優勢：不只是殺細胞，而是改寫細胞內蛋白命運","07｜但 DAC 的挑戰也很硬：CMC、生物學與治療窗，沒有一關容易","08｜DAC 最可能先在哪些疾病突破？","09｜台灣並的 ADC 與偶聯平台"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Linkedin","source":"","date":"","url":""},{"title":"Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes links to find associated clinical trials.","source":"","date":"","url":""},{"title":"www.cancer.gov","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"The emerging field of degrader-antibody conjugates","source":"","date":"","url":""},{"title":"Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech companies.","source":"","date":"","url":""},{"title":"www.labiotech.eu","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"C4 Therapeutics Expands Long-Term Partnership with Roche","source":"","date":"","url":""},{"title":"Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload...","source":"","date":"","url":""},{"title":"www.globenewswire.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"Press Release","source":"Firefly Bio Debuts With $94 Million Series A Financing","date":"","url":""},{"title":"Transformational degrader antibody conjugate company backed by founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly","source":"","date":"","url":""},{"title":"fireflybiologics.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Precision DACs - Prelude Therapeutics","source":"","date":"","url":""},{"title":"https://preludetx.com/science/precisiondacs/","source":"","date":"","url":"https://preludetx.com/science/precisiondacs/"},{"title":"preludetx.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？","url":"https://drugnews.com.tw/assets/articles/dac-adc-protac-next-targeted-therapy/dcard-01.webp"},{"alt":"Dcard 原圖：DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？","url":"https://drugnews.com.tw/assets/articles/dac-adc-protac-next-targeted-therapy/dcard-02.png"},{"alt":"Dcard 原圖：DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？","url":"https://drugnews.com.tw/assets/articles/dac-adc-protac-next-targeted-therapy/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dac-adc-protac-next-targeted-therapy/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-11）。DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？。https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-11-dac-adc-protac-next-targeted-therapy-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}